fb-pixel
Vertex Pharmaceuticals’s waterfront headquarters
Vertex Pharmaceuticals’s waterfront headquartersGlobe staff/file 2013

Shares of Vertex Pharmaceuticals Inc. skyrocketed following the release of a phase 3 clinical trial that showed a combination of two cystic fibrosis drugs it developed helped people with the deadly disease breathe more easily, raising hopes the treatment could be on the market by late next year. CEO Jeffrey Leiden said the encouraging study results mean the company is likely to file for approval of the treatment in the United States and Europe by the end of the year, and will seek priority review by regulators.